Amphastar Pharmaceuticals Inc. (AMPH) Stock Falls on Q4 2025 Earnings

Amphastar Pharmaceuticals Inc. (AMPH) reported Q4 2025 results with total revenue of $183.1 million, down 1.8% year-over-year, and diluted earnings per share of $0.51, a decline of 31.1% versus the prior year. The quarter missed analyst expectations, with consensus revenue of $194.3 million and an EPS estimate of $0.94.

Total revenue: $183.1 million (-1.8% YoY)

Gross profit: $85.7 million (-1.1% YoY)

Operating profit: $35.6 million (-21.1% YoY)

Net income attributable to common shareholders: $24.4 million (-35.7% YoY)

Diluted EPS: $0.51 (-31.1% YoY)

Cash flow and balance sheet highlights show stronger cash generation and a stable cash position.

Cash from operating activities: $52.6 million (+81.2% YoY)

Purchases of property, plant and equipment: $5.3 million (down 56.9% YoY)

Cash and cash equivalents: $170.2 million (+12.3% YoY)

Total liabilities: $840.5 million (down 0.6% YoY)

Key takeaways:

AMPH missed both revenue and EPS expectations for the quarter, weighing on near-term sentiment.

Margins compressed as operating profit fell more than 20% year-over-year.

Underlying cash generation strengthened, with operating cash flow up more than 80% year-over-year, helping support the balance sheet despite weaker earnings.

Following the release, the stock moved sharply lower, with price change since market close of -16.95%.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Amphastar Pharmaceuticals Inc. Insider Trading Activity

Amphastar Pharmaceuticals Inc. insiders have traded $AMPH stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $AMPH stock by insiders over the last 6 months:

FLOYD F. PETERSEN has made 0 purchases and 6 sales selling 22,342 shares for an estimated $591,072.
RONG ZHOU (SENIOR EVP, PRODUCTION CENTER) sold 9,787 shares for an estimated $256,379
RICHARD K PRINS sold 4,179 shares for an estimated $113,253

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Amphastar Pharmaceuticals Inc. Hedge Fund Activity

We have seen 112 institutional investors add shares of Amphastar Pharmaceuticals Inc. stock to their portfolio, and 148 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC removed 407,092 shares (-58.3%) from their portfolio in Q4 2025, for an estimated $10,901,923
AMERICAN CENTURY COMPANIES INC added 376,751 shares (+130.6%) to their portfolio in Q4 2025, for an estimated $10,089,391
MARSHALL WACE, LLP added 363,216 shares (+41.6%) to their portfolio in Q4 2025, for an estimated $9,726,924
GOLDMAN SACHS GROUP INC added 315,481 shares (+130.8%) to their portfolio in Q4 2025, for an estimated $8,448,581
ALGERT GLOBAL LLC removed 267,772 shares (-68.2%) from their portfolio in Q4 2025, for an estimated $7,170,934
PRICE T ROWE ASSOCIATES INC /MD/ removed 238,426 shares (-86.6%) from their portfolio in Q4 2025, for an estimated $6,385,048
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 167,116 shares (+42.6%) to their portfolio in Q4 2025, for an estimated $4,475,366

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Amphastar Pharmaceuticals Inc. Analyst Ratings

Wall Street analysts have issued reports on $AMPH in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 11/07/2025

To track analyst ratings and price targets for Amphastar Pharmaceuticals Inc., check out Quiver Quantitative's $AMPH forecast page.

Amphastar Pharmaceuticals Inc. Price Targets

Multiple analysts have issued price targets for $AMPH recently. We have seen 2 analysts offer price targets for $AMPH in the last 6 months, with a median target of $32.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $30.0 on 12/09/2025
Serge Belanger from Needham set a target price of $34.0 on 11/07/2025